Two San Fernando Valley physicians have consented to plead guilty to federal charges declaring they acquired more than $1 million in unlawful and possibly hazardous cancer drugs not authorized for circulation in the United States.
Dr. Stanley Rossman and Dr. Mark Goldstein, who operated Hematology Oncology Consultants in West Hills and Van Nuys, confessed last month that from 2008 to 2011 they acquired Altuzan, meant for foreign markets such as Turkey, according to a plea arrangement.
The Food and Drug Administration had actually not authorized Altuzan for distribution and explained the pharmaceutical as possibly counterfeit and hazardous.
Rossman and Goldstein have actually not officially entered guilty pleas and are slated to appear Friday, Feb. 19, in U.S. District Court in Los Angeles. Info was not right away offered from district attorneys describing the length of time between the alleged offenses and the completed plea arrangement.
District attorneys prepare to ask the court to sentence Rossman and Goldstein to one year of probation and require them to pay $1.2 million in fines and loss on behalf of Hematology Oncology. Both physicians likewise might face suspension or revocation of their medical licenses, according to the plea arrangement.
No previous disciplinary action has actually been taken by the California Medical Board versus Rossman or Goldstein, said spokesman Carlos Villatoro, He declined to talk about the set’s plea agreement.
Vince Farhat, an attorney for Rossman, did not respond to emails and phone calls seeking remark. Douglas Axel, who is Goldstein’s lawyer, declined to go over the plea contract. Furthermore, Rossman and Goldstein might not be grabbed comment.
Drugs considered harmful by FDA
According to court records, Hematology Oncology acquired discounted cancer drugs from Montana Health care Solutions, a company in Belgrade, Montana, that sourced pharmaceuticals from foreign markets.
In March 2009, Hematology Oncology’s office manager informed an FDA private investigator she couldn’t keep in mind buying drugs from Montana Healthcare Solutions and only utilized “approved distributors,” the contract states. After the investigator’s see, the medical practice continued buying prohibited foreign market drugs from Montana Health care Solutions, according to district attorneys.
” Many of the billings from Montana Health care Solutions indicated that the drugs were suggested for foreign markets, such as Turkey or nations within the European Union, and some of the billings recognized the drugs by various names,” the plea contract states.
Hematology Oncology’s workplace manager placed orders for the foreign market prescription drugs due to the fact that the pharmaceuticals were lower in price than those offered from domestic providers, district attorneys said.
” The workplace supervisor– and, consequently, defendant– knew that a minimum of some of the drugs bought from Montana Health care Solutions were prohibited foreign market prescription drugs,” states the plea arrangement.
FDA cautioning letter
In February 2012, Montana Health care Solutions sent an alert to the defendants that some of the cancer drugs it had delivered were likely counterfeit and did not include the medication’s active ingredient, bevacizumab.
2 months later, the FDA sent a warning letter to Goldstein requiring that he stop using Altuzan bought from Montana Health care Solutions.
” Buying prescription drug items, such as cancer medications, from foreign or unlicensed suppliers puts clients at threat of direct exposure to drugs that may be fake, polluted, incorrectly stored and transferred, inadequate, and dangerous,” the letter says.
Canada Drugs Ltd., which obtained Montana Healthcare Solutions, pleaded guilty in 2018 to prohibited sales of misbranded and counterfeit prescription pharmaceuticals that were unapproved in the U.S.